Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: grozinger k. J Cancer Res Clin Oncol. 2021 Apr;147(4):1273-1274. doi: 10.1007/s00432-021-03549-y. J Cancer Res Clin Oncol. 2021. PMID: 33625578 Free PMC article. No abstract available.
Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial.
Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M. Albers P, et al. Among authors: grozinger k. World J Urol. 2021 Jan;39(1):65-72. doi: 10.1007/s00345-020-03154-7. Epub 2020 Mar 18. World J Urol. 2021. PMID: 32189088 Free PMC article. Clinical Trial.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: grozinger k. J Cancer Res Clin Oncol. 2021 Jan;147(1):235-242. doi: 10.1007/s00432-020-03327-2. Epub 2020 Sep 4. J Cancer Res Clin Oncol. 2021. PMID: 32886212 Free PMC article. Clinical Trial.
Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: grozinger k. J Cancer Res Clin Oncol. 2021 Jan;147(1):243-244. doi: 10.1007/s00432-020-03497-z. J Cancer Res Clin Oncol. 2021. PMID: 33346877 Free PMC article. No abstract available.
Challenges and potential for RNA nanoparticles (RNPs).
Davis D, Akhtar U, Keaster B, Grozinger K, Washington L, Kelsey S, Sarkar A, DeLong RK. Davis D, et al. Among authors: grozinger k. J Biomed Nanotechnol. 2009 Feb;5(1):36-44. doi: 10.1166/jbn.2009.1005. J Biomed Nanotechnol. 2009. PMID: 20055104 Review.
Synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid vinyl-ACCA) derivatives: key intermediates for the preparation of inhibitors of the hepatitis C virus NS3 protease.
Beaulieu PL, Gillard J, Bailey MD, Boucher C, Duceppe JS, Simoneau B, Wang XJ, Zhang L, Grozinger K, Houpis I, Farina V, Heimroth H, Krueger T, Schnaubelt J. Beaulieu PL, et al. Among authors: grozinger k. J Org Chem. 2005 Jul 22;70(15):5869-79. doi: 10.1021/jo050468q. J Org Chem. 2005. PMID: 16018680
86 results